Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center
-
M Ghazi
,
G Khanbabaee
,
F Fallah
,
B Kazemi
,
S Mahmoudi
,
M Navidnia
,
B Pourakbari
,
B Bakhshi
,
H Goudarzi
Abstract
Background and Objectives: This study was carried out with the objective of determining the genomic variability of P. aeruginosa strains isolated from patients suffering from cystic fibrosis or from environmental cultures collected from different locations in the unit they admitted.
Materials and Methods: A total of 57 clinical and environmental P. aeruginosa isolates were genotyped by enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR), and antimicrobial susceptibility testing was performed using the Clinical and Laboratory Standards Institute method.
Results: One predominant ERIC profile (type A) was identified in 46 strains (81% of all typed isolates) which was responsible for thirty-nine of 44 clinical isolates (89%) and 7 of 13 environmental isolates (54%). All clinical isolates were susceptible to piperacillin-tazobactam, ceftazidime and cefepime followed by ticarcillin, aztreonam, amikacin and tobramycin (96.5%).
Conclusions: In our country CF patients are not segregated from other patients, and transmission of bacteria between these patients and other patients might occur in the wards via personal contact or contaminated environment. Future evaluation for policy of patient segregation is necessary and the elimination of contaminated sources and control of environmental spread and recurrent contamination risk is needed.
Mir TA, Ashraf M, Ahmed K, Chowdhary J, Rehana B, Ahmed J. Clinical profile, diagnostic delay, and genetic make-up of cystic fibrosis in Kashmir, India. Lung India 2011; 28: 97-100.
Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4 Suppl 2: 49-54.
Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9: 32.
Bradbury RS, Champion AC, Reid DW. Epidemiology of Pseudomonas aeruginosa in a tertiary referral teaching hospital. J Hosp Infect 2009; 73: 151-156.
Hafiane A, Ravaoarinoro M. Various typing methods of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Med Mal Infect 2008; 38: 238-247.
Kidd TJ, Grimwood K, Ramsay KA, Rainey PB, Bell SC. Comparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples from patients with cystic fibrosis. J Clin Microbiol 2011; 49: 263-268.
Stehling EG, Leite DS, Silveira WD. Molecular typing and biological characteristics of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Brazil. Braz J Infect Dis 2010; 14: 462-467.
(NCCLS) National Committee for Clinical Laboratory Standards. (2004). Performance standards for antimicro- bial susceptibility testing. Fourteenth informational supplement M100-S14. National Committee for Clinical Laboratory Standards, Wayne, Pa.
Syrmis MW, O’Carroll MR, Sloots TP, Coulter C, Wainwright CE, Bell SC, et al. Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive- element-based PCR assays. J Med Microbiol 2004; 53:1089-1096.
Bradbury RS, Tristram SG, Roddam LF, Reid DW, Inglis TJ, Champion AC. Antimicrobial susceptibility testing of cystic fibrosis and non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa: a comparison of three methods. Br J Biomed Sci 2011; 68: 1-4.
Tramper-Stranders GA, van der Ent CK, Wolfs TF, Kimpen JL, Fleer A, Johansen U, et al. Pseudomonas aeruginosa diversity in distinct paediatric patient groups. Clin Microbiol Infect 2008; 14: 935-941.
Cramer N, Wiehlmann L, Tummler B. Clonal epidemio- logy of Pseudomonas aeruginosa in cystic fibrosis. Int J Med Microbiol 2010; 300: 526-533.
Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee.2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35: S65-164.
O’Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Coulter C, et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004; 24: 101-106.
Jakobsson BM, Onnered AB, Hjelte L, Nyström B. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect 1997; 36:201-207.
Wolf MF, Simon A. The use of piperacillin-tazobactam in neonatal and paediatric patients. Expert Opin Drug Metab Toxicol 2009; 5: 57-69.
| Files | ||
| Issue | Vol 4 No 3 (2012) | |
| Section | Articles | |
| Keywords | ||
| Cystic fibrosis Iran P. aeruginosa genotyping | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
